Many diseases lack effective treatments that promote tissue regeneration and repair. Traditional therapies often manage symptoms without addressing the underlying cellular damage or loss of function. This unmet need drives the search for innovative regenerative medicine solutions.

Direct Biologics develops and manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells (MSCs). These EVs contain bioactive molecules that stimulate regenerative processes within the body. Their lead product, ExoFlo, is designed to improve treatment outcomes for various diseases by delivering clinically validated regenerative biologic solutions. Direct Biologics leverages its expertise in cellular and regenerative therapies to produce high-quality and safe EVs.

Extracellular vesicles (EVs) derived from adult human mesenchymal stem/stromal cells (MSCs)

cGMP manufacturing processes to ensure product quality and consistency

Bioactive molecules with therapeutic potential for regenerative medicine

ExoFlo product for various disease applications

The primary target audience includes medical professionals and researchers in the field of regenerative medicine seeking advanced biologic products for therapeutic applications.